目前针对阿尔茨海默病的多肽疫苗和免疫疗法。

IF 1.5 4区生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Peptide Science Pub Date : 2023-01-01 Epub Date: 2022-06-24 DOI:10.1002/pep2.24289

Chelsea Marie T Parrocha, James S Nowick

{"title":"目前针对阿尔茨海默病的多肽疫苗和免疫疗法。","authors":"Chelsea Marie T Parrocha, James S Nowick","doi":"10.1002/pep2.24289","DOIUrl":null,"url":null,"abstract":"Peptide vaccines and immunotherapies against aggregating proteins involved in the pathogenesis and progression of Alzheimer's disease (AD) - the β-amyloid peptide (Aβ) and tau - are promising therapeutic avenues against AD. Two decades of effort has led to the controversial FDA approval of the monoclonal antibody Aducanumab (Aduhelm), which has subsequentially sparked the revival and expedited review of promising monoclonal antibody immunotherapies that target Aβ. In this review, we explore the development of Aβ and tau peptide vaccines and immunotherapies with monoclonal antibodies in clinical trials against AD.","PeriodicalId":19825,"journal":{"name":"Peptide Science","volume":"115 1","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916509/pdf/","citationCount":"0","resultStr":"{\"title\":\"Current Peptide Vaccine and Immunotherapy Approaches Against Alzheimer's Disease.\",\"authors\":\"Chelsea Marie T Parrocha, James S Nowick\",\"doi\":\"10.1002/pep2.24289\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Peptide vaccines and immunotherapies against aggregating proteins involved in the pathogenesis and progression of Alzheimer's disease (AD) - the β-amyloid peptide (Aβ) and tau - are promising therapeutic avenues against AD. Two decades of effort has led to the controversial FDA approval of the monoclonal antibody Aducanumab (Aduhelm), which has subsequentially sparked the revival and expedited review of promising monoclonal antibody immunotherapies that target Aβ. In this review, we explore the development of Aβ and tau peptide vaccines and immunotherapies with monoclonal antibodies in clinical trials against AD.\",\"PeriodicalId\":19825,\"journal\":{\"name\":\"Peptide Science\",\"volume\":\"115 1\",\"pages\":\"\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916509/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Peptide Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pep2.24289\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/6/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Peptide Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pep2.24289","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/24 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

针对参与阿尔茨海默病（AD）发病和进展的聚集蛋白--β-淀粉样蛋白肽（Aβ）和tau--的肽疫苗和免疫疗法是很有希望的AD治疗途径。经过二十年的努力，美国食品和药物管理局（FDA）批准了具有争议性的单克隆抗体阿杜单抗（Aduhelm），随后引发了针对 Aβ 的前景看好的单克隆抗体免疫疗法的复兴和加速审查。在这篇综述中，我们将探讨Aβ和tau肽疫苗的开发情况，以及正在进行临床试验的针对AD的单克隆抗体免疫疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Current Peptide Vaccine and Immunotherapy Approaches Against Alzheimer's Disease.

查看原文本刊更多论文

Current Peptide Vaccine and Immunotherapy Approaches Against Alzheimer's Disease.

Peptide vaccines and immunotherapies against aggregating proteins involved in the pathogenesis and progression of Alzheimer's disease (AD) - the β-amyloid peptide (Aβ) and tau - are promising therapeutic avenues against AD. Two decades of effort has led to the controversial FDA approval of the monoclonal antibody Aducanumab (Aduhelm), which has subsequentially sparked the revival and expedited review of promising monoclonal antibody immunotherapies that target Aβ. In this review, we explore the development of Aβ and tau peptide vaccines and immunotherapies with monoclonal antibodies in clinical trials against AD.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Peptide Science Biochemistry, Genetics and Molecular Biology-Biophysics

CiteScore

5.20

自引率

4.20%

发文量

期刊介绍： The aim of Peptide Science is to publish significant original research papers and up-to-date reviews covering the entire field of peptide research. Peptide Science provides a forum for papers exploring all aspects of peptide synthesis, materials, structure and bioactivity, including the use of peptides in exploring protein functions and protein-protein interactions. By incorporating both experimental and theoretical studies across the whole spectrum of peptide science, the journal serves the interdisciplinary biochemical, biomaterials, biophysical and biomedical research communities. Peptide Science is the official journal of the American Peptide Society.